Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
pubmed:
17
10
2018
medline:
29
1
2020
entrez:
17
10
2018
Statut:
ppublish
Résumé
Most studies on hepatitis C virus (HCV)/HIV-coinfection do not account for the order and duration of these two infections. We aimed to assess the effect of incident HCV infection, and its timing relative to HIV seroconversion (HIVsc) in HIV-positive MSM on their subsequent CD4+ T-cell count and HIV RNA viral load trajectories. We included MSM with well estimated dates of HIVsc from 17 cohorts within the CASCADE Collaboration. HCV-coinfected MSM were matched to as many HIV monoinfected MSM as possible by HIV-infection duration and combination antiretroviral therapy (cART) use. We used multilevel random-effects models stratified by cART use to assess differences in CD4+ cell count and HIV RNA viral load trajectories by HCV-coinfection status. We matched 214 (ART-naive) and 147 (on cART) HCV-coinfected MSM to 5384 and 3954, respectively, matched controls. The timing of HCV seroconversion (HCVsc) relative to HIVsc had no demonstrable effect on HIV RNA viral load or CD4+ cell count trajectories. In the first 2-3 years following HCVsc CD4 cell counts were lower among HCV-coinfected MSM, but became comparable with HIV monoinfected MSM thereafter. In ART-naive MSM, during the first 2 years after HCVsc, HIV RNA viral load levels were lower or comparable with HIV monoinfected, tending to be higher thereafter. In MSM on cART, HCV had no significant effect on having a detectable HIV RNA viral load. Irrespective of the duration of HIV infection when HCV is acquired, CD4+ cell counts were temporarily lower following HCVsc, even when on cART. The clinical implications of our findings remain to be further elucidated.
Sections du résumé
BACKGROUND
Most studies on hepatitis C virus (HCV)/HIV-coinfection do not account for the order and duration of these two infections. We aimed to assess the effect of incident HCV infection, and its timing relative to HIV seroconversion (HIVsc) in HIV-positive MSM on their subsequent CD4+ T-cell count and HIV RNA viral load trajectories.
METHODS
We included MSM with well estimated dates of HIVsc from 17 cohorts within the CASCADE Collaboration. HCV-coinfected MSM were matched to as many HIV monoinfected MSM as possible by HIV-infection duration and combination antiretroviral therapy (cART) use. We used multilevel random-effects models stratified by cART use to assess differences in CD4+ cell count and HIV RNA viral load trajectories by HCV-coinfection status.
FINDINGS
We matched 214 (ART-naive) and 147 (on cART) HCV-coinfected MSM to 5384 and 3954, respectively, matched controls. The timing of HCV seroconversion (HCVsc) relative to HIVsc had no demonstrable effect on HIV RNA viral load or CD4+ cell count trajectories. In the first 2-3 years following HCVsc CD4 cell counts were lower among HCV-coinfected MSM, but became comparable with HIV monoinfected MSM thereafter. In ART-naive MSM, during the first 2 years after HCVsc, HIV RNA viral load levels were lower or comparable with HIV monoinfected, tending to be higher thereafter. In MSM on cART, HCV had no significant effect on having a detectable HIV RNA viral load.
INTERPRETATION
Irrespective of the duration of HIV infection when HCV is acquired, CD4+ cell counts were temporarily lower following HCVsc, even when on cART. The clinical implications of our findings remain to be further elucidated.
Identifiants
pubmed: 30325767
doi: 10.1097/QAD.0000000000002040
pmc: PMC7116662
mid: EMS113479
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
327-337Subventions
Organisme : Wellcome Trust
ID : 203077
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U122886351
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12023/15
Pays : United Kingdom
Références
AIDS. 2010 Jul 31;24(12):1857-65
pubmed: 20479633
HIV Med. 2000 Oct;1(4):224-31
pubmed: 11737353
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
J Hepatol. 2017 Jul;67(1):23-31
pubmed: 28235612
AIDS. 2008 Oct 18;22(16):2179-85
pubmed: 18832881
Curr HIV/AIDS Rep. 2011 Mar;8(1):12-22
pubmed: 21221855
J Hepatol. 2017 Aug;67(2):255-262
pubmed: 28412290
J Infect Dis. 2016 Oct 15;214(8):1134-6
pubmed: 27485355
BMC Immunol. 2013 May 17;14:23
pubmed: 23679118
J Int AIDS Soc. 2016 Sep 19;19(1):20944
pubmed: 27649908
Gastroenterology. 2013 Apr;144(4):751-760.e2
pubmed: 23266560
J Viral Hepat. 2013 Oct;20(10):715-24
pubmed: 24010646
Lancet Infect Dis. 2010 Jul;10(7):455-63
pubmed: 20610327
AIDS. 2014 Mar 13;28(5):781-90
pubmed: 24832014
HIV Med. 2017 Apr;18(4):284-291
pubmed: 27477612
Antivir Ther. 2012;17(8):1541-50
pubmed: 22869294
PLoS One. 2015 Jul 30;10(7):e0132772
pubmed: 26225723
AIDS. 2015 Nov;29(17):2335-45
pubmed: 26258525
AIDS. 2008 Oct 1;22(15):1979-91
pubmed: 18784461
J Viral Hepat. 2017 Oct;24(10):832-839
pubmed: 28439936
Clin Infect Dis. 2012 Feb 15;54(4):539-47
pubmed: 22157174
AIDS. 2010 Jul 31;24(12):1799-812
pubmed: 20601854
J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):536-42
pubmed: 25559595
BMC Infect Dis. 2016 Sep 05;16:471
pubmed: 27595855
Clin Sci (Lond). 2009 May 14;116(12):861-70
pubmed: 19128241
Clin Infect Dis. 2013 Apr;56(7):1038-43
pubmed: 23264364
J Infect Dis. 2008 Sep 1;198(5):683-6
pubmed: 18627270
BMC Public Health. 2014 Jan 06;14:3
pubmed: 24393532